NKTR
Nektar Therapeutics
Price:  
1.17 
USD
Volume:  
951,957.00
United States | Pharmaceuticals
Valuation
Overview
Financials
Forecast
Compare
Historical Price
SolvencyDividends
Transactions
People

NKTR EV/EBITDA

-1136.7%
Upside

As of 2024-06-17, the EV/EBITDA ratio of Nektar Therapeutics (NKTR) is -1.26. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. NKTR's latest enterprise value is 166.19 mil USD. NKTR's TTM EBITDA according to its financial statements is -131.94 mil USD. Dividing these 2 quantities gives us the above NKTR EV/EBITDA ratio.

Note: valuation result may not be accurate due to the company's negative EBITDA.

Range Selected
Trailing P/E multiples 9.9x - 18.2x 14.4x
Forward P/E multiples 18.7x - 20.4x 20.1x
Fair Price (13.17) - (12.83) (12.13)
Upside -1225.8% - -1196.3% -1136.7%
1.17 USD
Stock Price
(12.13) USD
Fair Price

NKTR EV/EBITDA - Historical EV/EBITDA Data

Date EV/EBITDA
2024-06-14 -1.26
2024-06-13 -1.37
2024-06-12 -1.43
2024-06-11 -1.38
2024-06-10 -1.31
2024-06-07 -1.38
2024-06-06 -1.57
2024-06-05 -1.61
2024-06-04 -1.58
2024-06-03 -1.59
2024-05-31 -1.40
2024-05-30 -1.38
2024-05-29 -1.55
2024-05-28 -1.72
2024-05-24 -1.91
2024-05-23 -1.94
2024-05-22 -2.07
2024-05-21 -2.00
2024-05-20 -2.07
2024-05-17 -2.07
2024-05-16 -2.14
2024-05-15 -2.18
2024-05-14 -2.09
2024-05-13 -2.07
2024-05-10 -2.08
2024-05-09 -1.86
2024-05-08 -1.91
2024-05-07 -1.72
2024-05-06 -1.93
2024-05-03 -1.82
2024-05-02 -1.96
2024-05-01 -1.93
2024-04-30 -1.66
2024-04-29 -1.66
2024-04-26 -1.47
2024-04-25 -1.47
2024-04-24 -1.55
2024-04-23 -1.61
2024-04-22 -1.52
2024-04-19 -1.36
2024-04-18 -1.47
2024-04-17 -1.51
2024-04-16 -1.71
2024-04-15 -1.82
2024-04-12 -1.96
2024-04-11 -1.83
2024-04-10 -1.43
2024-04-09 -1.37
2024-04-08 -1.45
2024-04-05 -1.47